Winslow Evans & Crocker Inc. Trims Holdings in bluebird bio Inc (BLUE)
Winslow Evans & Crocker Inc. lowered its position in bluebird bio Inc (NASDAQ:BLUE) by 60.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,500 shares of the biotechnology company’s stock after selling 2,300 shares during the quarter. Winslow Evans & Crocker Inc.’s holdings in bluebird bio were worth $267,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of BLUE. FMR LLC lifted its stake in bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares during the last quarter. Capital Research Global Investors lifted its stake in bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of bluebird bio by 10.7% during the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after purchasing an additional 343,856 shares during the last quarter. Eagle Asset Management Inc. purchased a new stake in shares of bluebird bio during the third quarter worth approximately $29,539,000. Finally, American Century Companies Inc. purchased a new stake in shares of bluebird bio during the third quarter worth approximately $31,170,000.
bluebird bio Inc (NASDAQ:BLUE) opened at $175.95 on Friday. The firm has a market capitalization of $7,790.00, a price-to-earnings ratio of -25.10 and a beta of 2.08. bluebird bio Inc has a twelve month low of $64.15 and a twelve month high of $222.03.
bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). The firm had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The firm’s revenue for the quarter was up 397.4% on a year-over-year basis. During the same period last year, the company posted ($2.07) EPS. research analysts predict that bluebird bio Inc will post -6.72 earnings per share for the current fiscal year.
Several research firms have recently commented on BLUE. BidaskClub cut bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Oppenheimer restated a “hold” rating on shares of bluebird bio in a research note on Tuesday, January 9th. CIBC began coverage on bluebird bio in a research note on Thursday, December 21st. They set a “market perform” rating for the company. Maxim Group cut bluebird bio from a “buy” rating to a “hold” rating and set a $200.00 price target for the company. in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Finally, Barclays restated an “overweight” rating and set a $209.00 price target (up previously from $162.00) on shares of bluebird bio in a research note on Wednesday, December 13th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $157.45.
In other bluebird bio news, COO Susanna Gatti High sold 1,282 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $172.15, for a total value of $220,696.30. Following the sale, the chief operating officer now owns 13,718 shares of the company’s stock, valued at $2,361,553.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nick Leschly sold 5,435 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $173.38, for a total value of $942,320.30. Following the completion of the sale, the chief executive officer now directly owns 171,009 shares in the company, valued at approximately $29,649,540.42. The disclosure for this sale can be found here. Insiders sold 208,095 shares of company stock worth $36,841,014 in the last three months. 3.90% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Winslow Evans & Crocker Inc. Trims Holdings in bluebird bio Inc (BLUE)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at https://www.dailypolitical.com/2018/01/20/winslow-evans-crocker-inc-trims-holdings-in-bluebird-bio-inc-blue.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.